LF
MCID: LSS003
MIFTS: 43

Lassa Fever (LF)

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Lassa Fever

MalaCards integrated aliases for Lassa Fever:

Name: Lassa Fever 12 76 59 55 3 44 15 73
Lassa Hemorrhagic Fever 59
Lf 59

Characteristics:

Orphanet epidemiological data:

59
lassa fever
Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 59  
Rare infectious diseases


Summaries for Lassa Fever

CDC : 3 Lassa fever is endemic in parts of west Africa including Sierra Leone, Liberia, Guinea and Nigeria; however, other neighboring countries are also at risk, as the animal vector for Lassa virus, the "multimammate rat" (Mastomys natalensis) is distributed throughout the region. In 2009, the first case from Mali was reported in a traveler living in southern Mali; Ghana reported its first cases in late 2011. Isolated cases have also been reported in Côte d’Ivoire and Burkina Faso and there is serologic evidence of Lassa virus infection in Togo and Benin.

MalaCards based summary : Lassa Fever, also known as lassa hemorrhagic fever, is related to lymphocytic choriomeningitis and hemorrhagic fever, and has symptoms including fever, vomiting and abdominal pain. An important gene associated with Lassa Fever is DAG1 (Dystroglycan 1), and among its related pathways/superpathways is Post-translational modification- synthesis of GPI-anchored proteins. The drugs Ribavirin and Antimetabolites have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and t cells, and related phenotypes are seizures and nausea and vomiting

Disease Ontology : 12 A viral infectious disease that results in infection, has material basis in Lassa virus, which is transmitted by multimammate rat of the genus Mastomys. The infection has symptom fever, has symptom retrosternal pain, has symptom sore throat, has symptom back pain, has symptom cough, has symptom abdominal pain, has symptom vomiting, has symptom diarrhea, has symptom conjunctivitis, has symptom facial swelling, has symptom proteinuria (protein in the urine), and has symptom mucosal bleeding.

Wikipedia : 76 Lassa fever, also known as Lassa hemorrhagic fever (LHF), is a type of viral hemorrhagic fever caused by... more...

Related Diseases for Lassa Fever

Diseases related to Lassa Fever via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 18)
# Related Disease Score Top Affiliating Genes
1 lymphocytic choriomeningitis 29.9 AXL DAG1
2 hemorrhagic fever 11.7
3 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.3
4 viral infectious disease 10.3
5 sensorineural hearing loss 10.2
6 vaccinia 10.2
7 encephalopathy 10.2
8 ebola hemorrhagic fever 10.1
9 diabetes mellitus, noninsulin-dependent 10.0
10 diabetes mellitus 10.0
11 hepatitis 10.0
12 rabies 10.0
13 hepatitis a 10.0
14 rift valley fever 10.0
15 coccidioidomycosis 10.0
16 smallpox 10.0
17 stomatitis 10.0
18 yellow fever 10.0

Graphical network of the top 20 diseases related to Lassa Fever:



Diseases related to Lassa Fever

Symptoms & Phenotypes for Lassa Fever

Symptoms:

12 (show all 12)
  • fever
  • vomiting
  • abdominal pain
  • back pain
  • diarrhea
  • conjunctivitis
  • cough
  • sore throat
  • mucosal bleeding
  • facial swelling
  • retrosternal pain
  • proteinuria (protein in the urine)

Human phenotypes related to Lassa Fever:

59 32 (show all 29)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 seizures 59 32 occasional (7.5%) Occasional (29-5%) HP:0001250
2 nausea and vomiting 59 32 frequent (33%) Frequent (79-30%) HP:0002017
3 hearing impairment 59 32 occasional (7.5%) Occasional (29-5%) HP:0000365
4 increased intracranial pressure 59 32 occasional (7.5%) Occasional (29-5%) HP:0002516
5 fever 59 32 hallmark (90%) Very frequent (99-80%) HP:0001945
6 fatigue 59 32 hallmark (90%) Very frequent (99-80%) HP:0012378
7 subcutaneous nodule 59 32 frequent (33%) Frequent (79-30%) HP:0001482
8 arthralgia 59 32 frequent (33%) Frequent (79-30%) HP:0002829
9 abdominal pain 59 32 frequent (33%) Frequent (79-30%) HP:0002027
10 thrombocytopenia 59 32 frequent (33%) Frequent (79-30%) HP:0001873
11 myalgia 59 32 frequent (33%) Frequent (79-30%) HP:0003326
12 palpebral edema 59 32 frequent (33%) Frequent (79-30%) HP:0100540
13 chemosis 59 32 frequent (33%) Frequent (79-30%) HP:0012375
14 vertigo 59 32 frequent (33%) Frequent (79-30%) HP:0002321
15 gastrointestinal hemorrhage 59 32 occasional (7.5%) Occasional (29-5%) HP:0002239
16 chest pain 59 32 frequent (33%) Frequent (79-30%) HP:0100749
17 diarrhea 59 32 frequent (33%) Frequent (79-30%) HP:0002014
18 recurrent pharyngitis 59 32 frequent (33%) Frequent (79-30%) HP:0100776
19 conjunctivitis 59 32 frequent (33%) Frequent (79-30%) HP:0000509
20 skin rash 59 32 occasional (7.5%) Occasional (29-5%) HP:0000988
21 cough 59 32 frequent (33%) Frequent (79-30%) HP:0012735
22 lethargy 59 32 occasional (7.5%) Occasional (29-5%) HP:0001254
23 headache 59 32 frequent (33%) Frequent (79-30%) HP:0002315
24 lymphadenopathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0002716
25 spontaneous abortion 59 32 hallmark (90%) Very frequent (99-80%) HP:0005268
26 pleural effusion 59 32 occasional (7.5%) Occasional (29-5%) HP:0002202
27 leukopenia 59 32 frequent (33%) Frequent (79-30%) HP:0001882
28 menometrorrhagia 59 32 hallmark (90%) Very frequent (99-80%) HP:0400008
29 cardiorespiratory arrest 59 32 occasional (7.5%) Occasional (29-5%) HP:0006543

Drugs & Therapeutics for Lassa Fever

Drugs for Lassa Fever (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):


# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ribavirin Approved Phase 2,Not Applicable 36791-04-5 37542
2 Antimetabolites Phase 2,Not Applicable
3 Anti-Infective Agents Phase 2,Not Applicable
4 Antiviral Agents Phase 2,Not Applicable

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Treatment of Viral Hemorrhagic Fevers With Intravenous Ribavirin in Military Treatment Facilities Enrolling by invitation NCT00992693 Phase 2 Ribavirin (Virazole) Injection
2 Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers Not yet recruiting NCT03805984 Phase 1 INO-4500
3 Seroprevalence and Incidence of Lassa Fever in the Rural Commune of Sibirila, District of Bougouni, Mali Completed NCT02311387
4 Lassa Fever Clinical Course and Prognostic Factors in Nigeria Recruiting NCT03655561
5 Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever Enrolling by invitation NCT02483260 Not Applicable Ribavirin
6 Prevalence and Incidence of Lassa Virus Infection in Southern Mali Not yet recruiting NCT03783143

Search NIH Clinical Center for Lassa Fever

Cochrane evidence based reviews: lassa fever

Genetic Tests for Lassa Fever

Anatomical Context for Lassa Fever

MalaCards organs/tissues related to Lassa Fever:

41
Skin, Testes, T Cells, Lung, Neutrophil

Publications for Lassa Fever

Articles related to Lassa Fever:

(show top 50) (show all 317)
# Title Authors Year
1
Lassa fever in Nigeria: the tale of a reactive health system. ( 29739558 )
2018
2
Expression and X-Ray Structural Determination of the Nucleoprotein of Lassa Fever Virus. ( 28986833 )
2018
3
Nigeria hit by unprecedented Lassa fever outbreak. ( 29590055 )
2018
4
Predicting outcome and improving treatment for Lassa fever. ( 29523495 )
2018
5
Mortality Among Confirmed Lassa Fever Cases During the 2015-2016 Outbreak in Nigeria. ( 29267063 )
2018
6
Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development. ( 29581897 )
2018
7
Diagnostics for Lassa Fever: Detecting Host Antibody Responses. ( 28986826 )
2018
8
Deadly Lassa-fever outbreak tests Nigeria's revamped health agency. ( 29565399 )
2018
9
Early detection of Lassa fever: the need for point-of-care diagnostics. ( 29856352 )
2018
10
Movement Patterns of Small Rodents in Lassa Fever-Endemic Villages in Guinea. ( 29572697 )
2018
11
Lassa fever and global health security. ( 29582756 )
2018
12
Re-emerging Lassa fever outbreaks in Nigeria: Re-enforcing "One Health" community surveillance and emergency response practice. ( 29703243 )
2018
13
Lassa fever in Nigeria: the great unknown. ( 29486937 )
2018
14
Absence of Nosocomial Transmission of Imported Lassa Fever during Use of Standard Barrier Nursing Methods. ( 29775178 )
2018
15
Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever. ( 29651117 )
2018
16
Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: a retrospective, observational cohort study. ( 29523497 )
2018
17
The challenges of detecting and responding to a Lassa fever outbreak in an Ebola-affected setting. ( 29138016 )
2018
18
Mitigation of the global impact of Lassa fever: Have we investigated enough about this Arenavirus? - A bibliometric analysis of Lassa Fever research. ( 29944957 )
2018
19
Lassa fever-induced sensorineural hearing loss: A neglected public health and social burden. ( 29470486 )
2018
20
Mitigating the risks of global spread of Lassa fever at the 2018 Hajj pilgrimage. ( 29709659 )
2018
21
Current research for a vaccine against Lassa hemorrhagic fever virus. ( 30147299 )
2018
22
Discharge Criteria for Patient With Lassa Fever Infection. ( 29186289 )
2018
23
A Case of Lassa Fever Diagnosed at a Community Hospital-Minnesota 2014. ( 30035149 )
2018
24
Case Report: Imported Case of Lassa Fever - New Jersey, May 2015. ( 30062993 )
2018
25
Lessons Learnt from Epidemiological Investigation of Lassa Fever Outbreak in a Southwest State of Nigeria December 2015 to April 2016. ( 30094105 )
2018
26
Lassa fever outbreaks in Nigeria. ( 30111178 )
2018
27
Knowledge of Lassa fever and use of infection prevention and control facilities among health care workers during Lassa fever outbreak in Ondo State, Nigeria. ( 30197747 )
2018
28
Lassa Fever 2016 Outbreak in Plateau State, Nigeria-The Changing Epidemiology and Clinical Presentation. ( 30211144 )
2018
29
Post-epidemic awareness and knowledge of Lassa fever among residents in affected community in Ibadan, Oyo State, Nigeria. ( 30250364 )
2018
30
Critical role for cholesterol in Lassa fever virus entry identified by a novel small molecule inhibitor targeting the viral receptor LAMP1. ( 30265711 )
2018
31
Acute Abdomen in Pediatric Patients With Lassa Fever: Prevalence and Response to Nonoperative Management. ( 30272215 )
2018
32
Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever. ( 30310067 )
2018
33
Rodent control to fight Lassa fever: Evaluation and lessons learned from a 4-year study in Upper Guinea. ( 30399142 )
2018
34
Lassa fever outbreak in adolescents in North Central Nigeria: report of cases. ( 30515301 )
2018
35
Bibliometric analysis of global Lassa fever research (1970-2017): a 47 - year study. ( 30526510 )
2018
36
Moving Lassa Fever Research and Care Into the 21st Century. ( 28863471 )
2017
37
Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever. ( 28869611 )
2017
38
Lessons learnt from imported cases and onward transmission of Lassa fever in Europe support broader management of viral haemorrhagic fevers. ( 29019310 )
2017
39
Epidemic preparedness and management: A guide on Lassa fever outbreak preparedness plan. ( 29238121 )
2017
40
Knowledge Attitude and Practices Toward Lassa Fever Control and Prevention Among Residents of Ile-Ife, Southwest Nigeria. ( 28511600 )
2017
41
A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever. ( 29045192 )
2017
42
Lassa fever. ( 28701331 )
2017
43
Management of a Lassa fever outbreak, Rhineland-Palatinate, Germany, 2016. ( 29019309 )
2017
44
Understanding the cryptic nature of Lassa fever in West Africa. ( 28875769 )
2017
45
Laboratory Diagnosis of Lassa Fever. ( 28404674 )
2017
46
Emergence of Lassa Fever Disease in Northern Togo: Report of Two Cases in Oti District in 2016. ( 29391958 )
2017
47
Metabolomics analyses identify platelet activating factors and heme breakdown products as Lassa fever biomarkers. ( 28922385 )
2017
48
Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa Fever. ( 29017278 )
2017
49
Control measures following a case of imported Lassa fever from Togo, North Rhine Westphalia, Germany, 2016. ( 29019307 )
2017
50
Outbreak of lassa fever in Nigeria: measures for prevention and control. ( 27347299 )
2016

Variations for Lassa Fever

Expression for Lassa Fever

Search GEO for disease gene expression data for Lassa Fever.

Pathways for Lassa Fever

Pathways related to Lassa Fever according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
10.62 GP2 PIGC

GO Terms for Lassa Fever

Biological processes related to Lassa Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 viral entry into host cell GO:0046718 8.62 AXL DAG1

Molecular functions related to Lassa Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 virus receptor activity GO:0001618 8.62 AXL DAG1

Sources for Lassa Fever

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....